Fig. 1 · Structure

Documents & Downloads

Ouabain

Cat. No. A12755 CAS 630-60-4

a-K-ATPase inhibitor

Ouabain is a selective Na+, K+-ATPase inhibitor.

This product is currently unavailable.

Ask us for lead time and price.

Inquire about this product

Publications for Ouabain

2 publications citing this product

  1. Daniel J Pfau, .et al. , Autophagy Rep, 2025, 4(1):2473765 PMID: 40265045
  2. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ouabain binds an extracellularly accessible pocket of Na+,K+-ATPase. A pig-kidney enzyme structure places its steroid core between transmembrane segments αM1–6, supporting stabilization of the phosphorylated E2P state. [1]

Ouabain affinity depends on assay cations. For pig-kidney E2P Na+,K+-ATPase, calculated Kd values were 3 nM at 3 mM MgCl2, 171 nM with added 10 mM KCl, and 18 nM when MgCl2 was raised to 12 mM in the presence of 10 mM KCl. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
α3 Ki 15 nM
α2 Ki 41 nM

Ouabain Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Ouabain from 3 published references. In vitro models include purified pig-kidney Na+,K+-ATPase α1β1γ complex in the E2P state; purified pig-kidney Na+,K+-ATPase E2P membrane preparation.

Ouabain In Vitro Studies

After 1 µM ouabain pretreatment for 1 h, glycolytic extracellular acidification decreased by 52% in MDA-MB-231 and 38% in MCF-7 cells. The 21% decrease in HCC1954 cells did not reach significance, and murine 4T1 cells showed no significant change. Oxygen consumption was unchanged across the panel; a parallel acute viability assay found no significant loss of membrane integrity. [2]

Structural basis of ouabain binding to phosphorylated Na+,K+-ATPase

Biochemical assay · Purified pig-kidney Na+,K+-ATPase α1β1γ complex in the E2P state [1]

The ouabain-bound structure places the ligand between transmembrane segments αM1–6, with its lactone directed into the membrane and polar steroid contacts to αM1, αM2 and αM6. The authors interpret binding as stabilization of the E2P conformation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Resolution of the ouabain-bound enzyme structureX-ray diffraction resolution 3.4 Å (anisotropically truncated data; 3.9 Å along a* and b*, 3.4 Å along c*)[1]
Ouabain position and interactionsStructural observation Ouabain between αM1–6; polar steroid contacts include Gln111, Asn122 and Thr797.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 mM ouabain in membrane preincubation for crystallization
Method
X-ray crystallography of the ouabain-stabilized E2P complex; crystallization at 19 °C
Co-treatment
Inorganic phosphate and Mg2+ used to stabilize the enzyme state; a purified-protein preparation.
Reported limits
Ouabain supplier, lot, hydration state and preincubation duration are not specified in the inspected main-text methods. Crystallization concentration is not an inhibitory potency.
Methods and source locations

Compound reported in the paper: Ouabain; Compound label in the paper: ouabain

Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.

Figure 1B–E; Results and Discussion—Ouabain Binding Site; Materials and Methods—Crystallization and Data Collection; Structure Determination and Analysis

Resolution of the ouabain-bound enzyme structure: Molecular replacement, model refinement and electron-density interpretation — Introduction final paragraph; Materials and Methods—Structure Determination and Analysis; Figure 1C

Ouabain position and interactions: Electron-density maps and structural model; no mutation experiment in this record. — Results and Discussion—Ouabain Binding Site; Figure 1C

Cation-dependent apparent affinity of ouabain for the E2P enzyme

Biochemical assay · Purified pig-kidney Na+,K+-ATPase E2P membrane preparation [1]

Potassium lowered the reported affinity for ouabain; increasing Mg2+ partially countered that effect. The calculated dissociation constants describe defined cation conditions rather than a universal IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ouabain affinity without added KClCalculated Kd 3 nM (3 mM MgCl2)[1]
Ouabain affinity with 10 mM KCl at lower MgCl2Calculated Kd 171 nM (3 mM MgCl2 and 10 mM KCl)[1]
Ouabain affinity with 10 mM KCl at higher MgCl2Calculated Kd 18 nM (12 mM MgCl2 and 10 mM KCl)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Ouabain titration shown over 0–3 µM in Figure 3A; 3 or 12 mM MgCl2 with or without 10 mM KCl
Method
Equilibrium ouabain-binding analysis read out through residual ATPase activity
Co-treatment
Cation-condition comparisons: 3 mM MgCl2 without KCl; 3 mM MgCl2 plus 10 mM KCl; 12 mM MgCl2 plus 10 mM KCl.
Reported limits
Binding temperature, incubation time and full fitting/protocol details are delegated to the cited Yatime et al. 2011 method and were not retrieved here; no further assay conditions are inferred.
Methods and source locations

Compound reported in the paper: Ouabain; Compound label in the paper: ouabain

Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.

Figure 3A and caption; cation-competition discussion; Materials and Methods—Enzyme Preparation and Biochemical Experiments

Ouabain affinity without added KCl: Equilibrium binding / residual activity; Figure 3 data points are averages of at least three experiments ± SEM. — Figure 3A and caption; Materials and Methods—Enzyme Preparation and Biochemical Experiments

Ouabain affinity with 10 mM KCl at lower MgCl2: Same equilibrium comparison; reported fitted Kd, not a graph-derived IC50. — Figure 3A caption

Ouabain affinity with 10 mM KCl at higher MgCl2: Same equilibrium comparison; reported fitted Kd. — Figure 3A caption

Acute ouabain treatment alters glycolytic acidification in a model-dependent manner

Cell-based study · Human MDA-MB-231, HCC1954 and MCF-7 breast-cancer cells; murine 4T1 breast-cancer cells [2]

After 1 µM ouabain pretreatment for 1 h, glycolytic ECAR decreased significantly in MDA-MB-231 and MCF-7 cells. The HCC1954 decrease did not reach significance, and 4T1 ECAR was unchanged. OCR did not differ significantly in any of the four cell lines. A parallel 1-h trypan-blue assay found no significant acute viability loss.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Glucose-stimulated glycolytic ECAR in MDA-MB-231 cellsDecrease versus control 52% decrease; p = 0.006[2]
Glucose-stimulated glycolytic ECAR in MCF-7 cellsDecrease versus control 38% decrease; p = 0.015[2]
Glucose-stimulated glycolytic ECAR in HCC1954 cellsNonsignificant decrease 21% decrease; p = 0.08[2]
Glucose-stimulated glycolytic ECAR in murine 4T1 cellsNo significant difference p = 0.24[2]
OCR during the glucose time windowNo significant difference 4T1: p = 0.39; MDA-MB-231: p = 0.40; HCC1954: p = 0.66; MCF-7: p = 0.16[2]
Membrane-integrity viability after acute treatmentNo significant viability loss No significant difference after 1 µM ouabain for 1 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM ouabain
Exposure duration
1 h pretreatment; followed by medium exchange and 1 h equilibration before the Seahorse stress test
Method
Seahorse XFe24 glycolytic stress test; ECAR normalized to well DNA content using DRAQ5
Vehicle
No-ouabain control; ouabain stock solvent not specified in the inspected treatment methods.
Co-treatment
Ouabain pretreatment alone. Subsequent assay challenges: 10 mM glucose, 1 µM oligomycin and 100 mM 2-deoxy-D-glucose; these define the stress test rather than an anticancer combination treatment.
Reported limits
Hydration state, lot and ouabain stock solvent are not established. Published Figure 2 supplement cross-references are inconsistent; the relevant definitions and other-cell traces were located directly in SI Figures S7 and S9.
Methods and source locations

Compound reported in the paper: Ouabain; Compound label in the paper: ouabain

Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.

Methods—Cell culture and treatment protocols (Sec3), Trypan blue exclusion (Sec6), Extracellular Flux (Sec10); Results Sec17 and Sec19; Figures 1h and 2; publisher SI Figures S7 and S9

Glucose-stimulated glycolytic ECAR in MDA-MB-231 cells: Figure 2e; nested unpaired t-test; n = 3 biological repeats, each with n = 3 technical repeats. — Figure 2e caption; Results—Treatment effect of ouabain on extracellular acidification rate (Sec19)

Glucose-stimulated glycolytic ECAR in MCF-7 cells: Figure 2g; nested unpaired t-test; same biological/technical replication as Figure 2. — Figure 2g caption

Glucose-stimulated glycolytic ECAR in HCC1954 cells: Figure 2f; nested unpaired t-test; same replication as Figure 2. Not a significant reduction. — Figure 2f caption

Glucose-stimulated glycolytic ECAR in murine 4T1 cells: Figure 2d; nested unpaired t-test; same replication as Figure 2. — Figure 2d caption

OCR during the glucose time window: Simultaneous OCR measurement; nested unpaired t-test; same replication as Figure 2. — Figure 2d–g caption

Membrane-integrity viability after acute treatment: Trypan-blue exclusion control; figure labels ns. Exact viability percentages and n are not inferred from points. — Figure 1h and caption; Methods—Trypan blue exclusion (Sec6); Results—Ouabain cytotoxicity (Sec17)

Ouabain In Vivo Studies

In a C. elegans fertility assay, ouabain increased the proportion of hatched eggs in several signaling-pathway mutant strains but reduced it in wild-type N2 worms. This opposing response limits generalization from mutant phenotype rescue to beneficial effects across models. [3]

Ouabain has opposing fertility effects in mutant and wild-type C. elegans

Animal study · C. elegans N2 and JK3476 (Wnt-associated), JK1107/BS3164 (Notch-associated), SD939 (Ras–ERK-associated) mutant strains [3]

The proportion of hatched eggs increased with ouabain in the mutant strains relative to vehicle. In wild-type N2, ouabain and the other tested agents reduced the hatched-egg percentage. These are reproductive phenotypes and do not directly establish cancer efficacy or pathway inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hatched-egg proportion relative to vehicleQualitative phenotype response Increased in JK3476, JK1107, BS3164 and SD939; decreased in wild-type N2.[3]

Conditions shared by the study groups

Route
Plate exposure
Frequency
An initial plate addition is described; repeat dosing is not described.
Treatment course
Observed for 120 h after exposure and temperature shift from permissive 15 °C to restrictive 25 °C.
Vehicle
1% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ouabain versus vehicle in wild-type and mutant worms
100 µL of the ouabain test solution at the reported 400 µg/mL sublethal concentration per plate; final agar concentration is not given.
Vehicle-only negative control; PRI-724, DAPT-GSI and U0126 served as pathway-associated comparator controls.Ouabain increased the hatched-egg percentage in the mutant strains relative to vehicle, but decreased it in wild-type N2.[3]
Ouabain versus vehicle in wild-type and mutant worms
Model: C. elegans N2, JK3476, JK1107, BS3164 and SD939
Reported limits: Supplier assignment to ouabain, catalog identifier, lot, hydration state and final agar concentration are not given. Supplementary Table 2 was not retrieved; exact effect sizes/error-bar definitions are not extracted.
Methods and source locations

Compound reported in the paper: Ouabain; Compound label in the paper: ouabain

Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.

Methods—Preparation of candidate drugs and Fertility bioassay; Table 3; Results—Candidate drugs increases fertility; Figure 5A–E

Hatched-egg proportion relative to vehicle: Figure 5; n = 20 per strain in caption; triplicate setups in methods. Methods describe one-way ANOVA with multiple comparisons; no precise ouabain pairwise p value or effect size is adopted without Supplementary Table 2. — Results—Candidate drugs increases fertility of C. elegans mutant strains; Figure 5A–E and caption; Methods—Fertility bioassay

Ouabain versus vehicle in wild-type and mutant worms · Methods—Preparation of candidate drugs; Fertility bioassay; Table 3; Results—Candidate drugs increases fertility; Figure 5

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 630-60-4
Applications a-K-ATPase inhibitor
Formula C29H44O12
Molecular Weight 584.66
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 87 mg/mL (119.37 mM)
Water Insoluble
Ethanol 87 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ouabain Research References

  1. [1] Laursen M, Yatime L, Nissen P, et al. Crystal structure of the high-affinity Na+,K+-ATPase–ouabain complex with Mg2+ bound in the cation binding site Proceedings of the National Academy of Sciences of the United States of America (2013). PMID: 23776223 DOI: 10.1073/pnas.1222308110 Source material
  2. [2] Michaels AM, Zoccarato A, Hoare Z, et al. Disrupting Na+ ion homeostasis and Na+/K+ ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo Cancer & metabolism (2024). PMID: 38783368 DOI: 10.1186/s40170-024-00343-5 Source material
  3. [3] Medina PM, Ponce JM, Cruz CA. Revealing the anticancer potential of candidate drugs in vivo using Caenorhabditis elegans mutant strains Translational oncology (2021). PMID: 33221682 DOI: 10.1016/j.tranon.2020.100940 Source material

Publications

2 publications citing this product

  1. Daniel J Pfau, .et al. , Autophagy Rep, 2025, 4(1):2473765 PMID: 40265045
  2. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682

Added to your cart

View Cart Checkout
Loading...